News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


BioReliance Corporation Announces Large Scale, Commercial Manufacturing Agreement (PR Newswire) ... MediGene`s anti-cancer therapeutics currently undergoing human clinical trials for the treatment of brain tumors and colorectal metastasis to the liver.... - Aug 15 9:50 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010815/cgw033.html

Posted on: 08/15/2001

"Yahoo - BioReliance Corporation Announces Large Scale, Commercial Manufacturing Agreement"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
BREL
12.45
+0.00
delayed 20 mins - disclaimer

Wednesday August 15, 9:50 am Eastern Time

Press Release

SOURCE: BioReliance Corporation

BioReliance Corporation Announces Large Scale, Commercial Manufacturing Agreement

ROCKVILLE, Md., Aug. 15 /PRNewswire/ -- BioReliance Corporation (Nasdaq: BREL - news) today announced an agreement under which it will produce clinical supplies of Herpes Simplex Virus-derived G207 and NV1020 for the biopharmaceutical company MediGene. These products are two of MediGene's anti-cancer therapeutics currently undergoing human clinical trials for the treatment of brain tumors and colorectal metastasis to the liver. Both products are being developed by MediGene's wholly owned subsidiary MediGene, Inc. of San Diego, California. BioReliance will provide manufacturing and testing services for both products. Production will occur in BioReliance's recently commissioned cGMP facility in Rockville, Maryland, dedicated to the large-scale production of viral therapeutics including vaccines, gene therapy vectors and oncolytic agents.

Dr. Frank Tufaro, Executive Vice President and Managing Director of MediGene, Inc., stated, "As both G207 and NV1020 are moving ahead in their clinical development, optimizing the production of our high-quality therapeutics is key. We believe BioReliance can provide the high quality, GMP-grade clinical supplies required for our promising clinical programs using oncolytic Herpes Simplex Viruses to treat cancer. The agreement reflects MediGene's strategy to focus on the core competencies necessary for drug development -- such as research, process development, pre- clinical and clinical development -- and to use third party services for cost effective production of therapeutics."

Dr. John Gilly, Vice President Manufacturing Division for BioReliance added, "We are very pleased to be providing manufacturing and testing services for MediGene to support their cancer therapeutics program. We feel that by working with BioReliance, MediGene will have the manufacturing resources necessary to support clinical development and potentially commercial supply. Our investment in large-scale manufacturing services, formally offered in September 2000, provides clients with capabilities such as process development, bulk manufacturing, and final drug manufacturing for viral therapeutics. We feel this capacity, along with the technical and regulatory expertise provided by BioReliance, will help facilitate rapid commercialization of our clients' products."

BioReliance Corporation is a leading contract service organization providing manufacturing, testing and development services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. BioReliance believes that it is the largest provider of outsourcing services focused on the expanding biologics sector of the pharmaceutical industry. To receive the latest news and corporate developments on BioReliance, please visit the company's web site at http://www.bioreliance.com .

MediGene AG is a publicly quoted biopharmaceutical company (Nmarkt: MDG) with headquarters in Martinsried, Germany and a wholly owned subsidiary, MediGene, Inc., in San Diego, California. The group combines a broad, proprietary technology portfolio including the ITD, CVLP, AAV and HSV technologies, with seven product candidates in various stages of clinical development and believe it has built up core competence in cardiac and cancer diseases, two areas of high medical need and huge market potential. For further information on MediGene, please visit the company's web site at http://www.medigene.com .

Certain statements made in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance, or achievements, and may contain the words "believe," "anticipate," "expect," "estimate," "project," "will be," "will continue," "will likely result," or similar words or phrases. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Risks and uncertainties are detailed from time to time in reports filed by BioReliance with the Securities and Exchange Commission, including in its Forms 10-K and 10-Q. In addition to these risks, there can be no assurances that the contract between BioReliance and MediGene AG will be successful. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

SOURCE: BioReliance Corporation

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:BioReliance Corp (NasdaqNM:BREL - news)
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740